Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study (ACADEMIC)

AIMS: To demonstrate the noninferiority of alogliptin to acarbose, in terms of antidiabetic efficacy, in Chinese people with uncontrolled type 2 diabetes (T2D) and high cardiovascular risk. MATERIALS AND METHODS: ACADEMIC (NCT03794336) was a randomized, open‐label, phase IV study conducted at 46 sit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Bin, Gao, Weiguo, Wan, Hailong, Xu, Fengmei, Zhou, Rong, Zhang, Xia, Ji, Qiuhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314577/
https://www.ncbi.nlm.nih.gov/pubmed/35112779
http://dx.doi.org/10.1111/dom.14661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314577/
https://www.ncbi.nlm.nih.gov/pubmed/35112779
http://dx.doi.org/10.1111/dom.14661

Ejemplares similares